We're focusing on high-value natural products with pharmaceutical potential
eXoZymes is strategically building a portfolio of high-value business opportunities, creating ownership stakes in companies, joint-ventures, and licensing partnerships that leverage our breakthrough technology for massive competitive advantages in billion-dollar markets.
Natural Health Products
- $500-$5,000/kg compounds
- Rapidly growing market
Pharmaceutical Analogs
-
$5,000-$500,000+/kg compounds
-
Higher barriers to entry
The projects we currently have in our pipeline
NCT: Over-the-Counter
A rare natural product that activates the cell’s master metabolic control switch - finally available at scale. NCT opens a new category in metabolic wellness by addressing cellular energy efficiency rather than symptoms.
NCT: Pharma
A first-in-class approach to treating multiple metabolic diseases through a single upstream mechanism. Platform-enabled analogs of NCT unlock a previously inaccessible pharmaceutical pathway with clear acquisition relevance.
Non-intoxicating Cannabinoids
Novel, non-intoxicating molecules inspired by cannabinoid biology but unconstrained by traditional chemistry. The platform enables rapid exploration of new chemical space with multiple therapeutic and commercial pathways.
Santalene
A high-value fragrance molecule constrained by scarcity and unsustainable extraction. Cell-free production transforms santalene into a predictable, scalable ingredient while opening access to adjacent aromatic compounds.
From platform to commercial assets
eXoZymes is built to do more than invent molecules. The company is structured to systematically translate breakthrough biomanufacturing capabilities into high-value commercial assets across wellness, industrial, and pharmaceutical markets.
At the core of this strategy is a proprietary, cell-free biomanufacturing platform that makes previously rare, complex, or economically inaccessible molecules predictable, scalable, and cost-effective to produce. Around this core, eXoZymes applies a flexible, capital-light commercialization framework designed to maximize strategic optionality and long-term value creation.
Rather than forcing every opportunity into a single go-to-market template, eXoZymes deliberately selects the commercialization structure best suited to each molecule, market, and risk profile. This approach enables the company to pursue multiple high-value opportunities in parallel while maintaining focus on its core technology platform.
Rapidly maturing potential candidate molecules
This section gives you an overview of our current high-value business opportunities built on eXoZymes cell-free biomanufacturing platform.
In prototyping we test out a plethora of ideas to vet their potential. The best ideas get tested in the lab - does it work? From there the asset is being matured across science, production. and commercial groundwork. Finally the asset is decided whether to become a spin-out, joint-venture, or licensing deal - which impacts the resources required. In some cases an active compound can have multiple use-cases, for example both in nutraceutical and pharmaceutical markets.
In traditional biotech it takes years and tens of millions of dollars to mature a single candidate for clinical testing. Levering our breakthrough cell-free platform, we can go from prototype to candidate in months and at a fraction of the cost.
Three complementary commercialization pathways
Spin-Outs
Spin-outs are used when an opportunity supports the creation of a focused, standalone company with significant long-term value potential. In these cases, eXoZymes contributes proprietary technology, process know-how, and intellectual property, while the spin-out raises dedicated capital and builds an independent operating team.
This structure allows eXoZymes to retain meaningful equity exposure and upside, while limiting balance-sheet risk and preserving internal focus.
Joint-Ventures
Joint ventures are employed when strategic partners provide market access, infrastructure, or domain expertise that materially accelerates commercialization. In these structures, eXoZymes combines its platform and IP with a partner’s operational capabilities, allowing risk, capital requirements, and upside to be shared.
Joint ventures enable faster scaling and strong alignment between technology ownership and downstream execution.
Licensing
Licensing is used when partners are best positioned to commercialize an asset directly. eXoZymes licenses process technology, enzyme systems, or molecule-specific rights in exchange for upfront payments, milestones, royalties, or a combination thereof.
This pathway allows eXoZymes to monetize its platform at scale while remaining operationally lean and capital efficient.
A platform-of-platforms strategy
Together, these three pathways form a platform-of-platforms model. Each commercial asset strengthens the underlying technology, expands the intellectual property portfolio, and increases optionality across future programs.
The result is asymmetric upside: external capital and partners fund downstream commercialization, while eXoZymes retains control over the core platform and participates in value creation across multiple markets.
Want to be kept up to date?
We are excited to keep you updated with news tailored to your preferences. By subscribing to one or more streams, you'll receive information relevant to the areas you've selected. If you ever wish to update your preferences, you can do so at any time.